Cybin Says CYB003 Showed Clear Incremental Benefit Of Second Dose, Resulting In 4 Out Of 5 Patients In Remission From Their Depression At 6 Weeks
Portfolio Pulse from Benzinga Newsdesk
Cybin reported that 79% of patients were in remission from depression at 6 weeks after receiving two doses of CYB003 (12mg), indicating a clear incremental benefit from the second dose.
November 30, 2023 | 12:36 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cybin's CYB003 demonstrated significant efficacy in treating depression, with a second dose leading to remission in 79% of patients at 6 weeks.
The positive clinical results of CYB003 are likely to be viewed favorably by investors and could lead to increased investor confidence in Cybin's product pipeline, potentially driving the stock price up in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100